Development of an economical, single step synthesis of FAZA, a clinical hypoxia marker, and potential synthons to prepare its positional analogs

Letters in Drug Design and Discovery

Volumn 6, Issue 1, 2009, Pages 82-85

  Kumar, P ^a   Emami, S ^a,c   McEwan, A J B ^a   Wiebe, L I ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Azomycin nucleoside; FAZA; Hypoxia sensitizer; One step synthesis; Solvents' effect; Synthons

Indexed keywords

1 ALPHA (5' DEOXY 5' FLUOROARABINOFURANOSYL) 2 NITROIMIDAZOLE; CELL MARKER; FLUORINE 18; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CELL HYPOXIA; DRUG SYNTHESIS; HUMAN; HYPOXIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRODUCT RECOVERY; RADIOSENSITIZATION; REACTION ANALYSIS; REACTION OPTIMIZATION; SOLVENT EXTRACTION;

EID: 61849121946     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018009787158616     Document Type: Article

References (19)

1. Hockel, M.; Vaupel, P. Tumor Hypoxia: Definitions and current clinical, biologic and molecular aspects. J. Natl. Cancer Inst., 2001, 93, 266-76.
2. Bunn, H. F.; Poyton, R. O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev., 1996, 76, 839-85.
3. Dachs, G. U.; Stratford, I. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. J. Br. J. Cancer., 1996, 74, S126-S132.
4. Harris, A. www.nature.com/reviews/cancer. January 2002, 2, 38-47.
5. Gray, L. H.; Conger, A. D.; Ebert, M.; Hornsey, S.; Scott, O. C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol., 1953, 26, 638-48.
6. Groshar, D.; McEwan, A. J. B.; Parliament, M. B.; Urtasun, R. C.; Golberg, L. E.; Hoskinson, M.; Mercer, J. R.; Mannan, R. H.; Wiebe, L. I.; Chapman, J. D. Imaging tumor hypoxia and tumor perfusion. J. Nucl. Med., 1993, 34, 885-88.
7. Wiebe, L. I. PET Radiopharmaceuticals for Metabolic Imaging in Oncology. In PET and Molecular Imaging; International Symposium Series 1264C; Tanaka and Kuge, Eds.; Elsevier Science: USA, 2003, pp. 53-76.
8. Kumar, P.; Stypinski, D.; Xia, H.; McEwan, A. J. B.; Machulla, H-J.; Wiebe, L. I. Fluoroazomycin arabinoside (FAZA): Synthesis, H-2 and H-3 labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J. Labeled Compd. Radiopharm., 1999, 42, 3-16.
9. Reischl, G.; Ehrlichmann, W.; Bieg, C.; Kumar, P.; Wiebe, L. I.; Machulla, H-J. Preparation of the Hypoxia Imaging PET tracer [18F]-FAZA: Reaction parameters and automation. Appl. Radiat. Isot., 2005, 62, 897-901.
10. 18F-FAZA): The initial results of Phase I/II study (Unpublished results).
11. nd Annual Meeting of Society of Nuclear Medicine, Toronto, Canada. June 2005, 18.
12. Biaglow, J. E.; Varnes, M. E.; Roizen-Towle, L.; Clark, E. P.; Epp, E. R.; Astor, M. B.; Hall, E. J. Biochemistry of reduction of nitro heterocycles. Biochem. Pharmacol., 1986, 35, 77-90.
13. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumours. Nucl. Med. Biol., 2003, 30, 317-26.
14. 18F-Fluoroazamycin Arabinoside. J. Nucl. Med., 2005, 46, 106-13.
15. 18F-FAZA predicts success of hypoxia-directed radiochemotherapy using Tirapazamine. J. Nucl. Med., 2007, 48, 973-80.
16. (a) Curran, D. P. Fluorous reverse phase silica gel. A new tool for preparative separations in synthetic organic and organofluorine chemsitry. Synlett., 2001, 9, 1488.
17. (b) Curran, D. P. In Handbook of Fluorous Chemistry; Gladysz, J. A., Curran, D. P., Horváth, I. T., Ed.; Wiley-VCH: Weinheim, 2004; pp. 101-27.
18. Singh, R.P.; Shreeve, J.M. Recent advances in Nucleophilic fluorination reactions of organic compounds-Using Dexofluor and DAST. Synth. J. Syn. Org. Chem., 2003, 17, 2561-78.
19. Wiebe, L.I.; McEwan, A.J.M.; Kumar, P. Novel substituted 2-nitroimidazoles useful for hypoxic cell therapy and imaging. Int. Patent application # PCT/CA2006/000482. 2006, http://www.wipo.int/pctdb/ia. jsp?IA=CA2006000482.